Price
No data yet.
Social Signal Score
Revenue
$11.38M-5.85%Company Profile
- CEO
- Joseph Vincent Amato
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.76
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.12
Financials
Revenue
$11.38M-5.8%Net Income
$4.02M+30.5%EBITDA
$6.67M+116.7%Free Cash Flow
$4.90M+53.5%EPS (diluted)
$0.05-80.0%Shares Outstanding (diluted)
80.39M+556.8%Operating Expenses
$0.00Cash & Debt
$4.58MReturn of Capital
$16.88MDividend per Share
$0.09Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $26.72M | $20.22M | $0.66 |
| 2024 | $41.75M | $37.94M | $1.44 |
| 2023 | $22.35M | $3.72M | $0.14 |
| 2022 | $9.53M | $-33.49M | $-0.86 |
| 2021 | $29.51M | $26.80M | $0.69 |
| 2020 | $9.17M | $3.02M | $0.08 |
| 2019 | $25.51M | $22.53M | $1.15 |
| 2018 | $-834.7K | $-3.09M | $-0.16 |
| 2017 | $25.82M | $23.87M | $1.22 |
| 2016 | $29.24M | $27.36M | $1.40 |
| 2015 | $25.25M | $-14.23M | $-0.73 |
| 2014 | $27.02M | $16.16M | $0.83 |
| 2013 | $27.33M | $33.63M | $1.72 |
| 2012 | $27.51M | $41.86M | $2.14 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NHS's reported EPS growth of -8.7% a year over 13 years.
- EPS in 5 years
- $0.42
- Implied price
- $4.61
- Return from $5.95
- -5.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.29 — -61.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 7 | 9 | 11 | 13 | 15 |
|---|---|---|---|---|---|
| -18.7% | -22.7% | -18.7% | -15.4% | -12.5% | -10.0% |
| -13.7% | -18.0% | -13.7% | -10.2% | -7.1% | -4.4% |
| -8.7% | -13.2% | -8.7% | -5.0% | -1.8% | 1.1% |
| -3.7% | -8.5% | -3.7% | 0.2% | 3.6% | 6.6% |
| 1.3% | -3.7% | 1.3% | 5.4% | 9.0% | 12.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (2)
- Newsprnewswire.com·6h ago·Neutral
NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on September 30, 2026, has a record date of September 15, 2026, and has an ex-date of September 15, 2026.
View source ↗ - Newsprnewswire.com·4d ago·Negative
Neuberger High Yield Strategies Fund Announces Increase in Leverage NEW YORK, Aug. 27, 2026 /PRNewswire/ -- High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") announced today that its Board of Directors has approved a $25 million increase in the committed debt financing available under its revolving debt financing facility ("Revolving Loan Facility") with a major unaffiliated financial institution, as well as the issuance of $10 million in additional Mandatory Redeemable Preferred…
View source ↗
Insider trading
Open-market buys and sells by NHS officers and directors.
- Bought
- $702250.1bn
- Sold
- $1.2m
56 trades
1 trade
- Kocinski Chrisbought
- Kocinski Chrisbought
- Lind Josephbought
- Lind Josephbought
- Metlife Investment Management, Llcbought
- Saba Capital Management, L.p.sold
- Metlife Investment Management, Llcbought
- Metlife Investment Management, Llcbought
43 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.